RHHVF
July 25, 2024 - AI Summary
Undervalued by 136.1% based on the discounted cash flow analysis.
Market cap | $250.20 Billion |
---|---|
Enterprise Value | $283.04 Billion |
Dividend Yield | $10.97477 (3.76552795031056%) |
Earnings per Share | $10.32 |
Beta | 0.17 |
Outstanding Shares | 802,307,692 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 24.75 |
---|---|
PEG | -201 |
Price to Sales | 2.5 |
Price to Book Ratio | 7.12 |
Enterprise Value to Revenue | 2.74 |
Enterprise Value to EBIT | 9.6 |
Enterprise Value to Net Income | 14 |
Total Debt to Enterprise | 0.14 |
Debt to Equity | 1.25 |
No data
No data
Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ...